Your browser doesn't support javascript.
loading
Characterization of Phenotypic Variability in Becker Muscular Dystrophy for Clinical Practice and Towards Trial Readiness: A Two-Years Follow up Study.
Ricci, Giulia; Govoni, Alessandra; Torri, Francesca; Astrea, Guja; Buchignani, Bianca; Marinella, Gemma; Battini, Roberta; Manca, Maria Laura; Castiglione, Vincenzo; Giannoni, Alberto; Emdin, Michele; Siciliano, Gabriele.
Afiliación
  • Ricci G; Department of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy.
  • Govoni A; Neuromuscular and Rare Disease Unit, La Fondazione IRCCS Ca' Granda Ospedale Maggiore di Milano Policlinico, Milano, Italy.
  • Torri F; Department of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy.
  • Astrea G; Department of Developmental Neuroscience, IRCCS Stella Maris, Calambrone, Pisa, Italy.
  • Buchignani B; Department of Developmental Neuroscience, IRCCS Stella Maris, Calambrone, Pisa, Italy.
  • Marinella G; Department of Translational Research and of New Surgical and Medical Technologies Pisa University, Pisa, Italy.
  • Battini R; Department of Developmental Neuroscience, IRCCS Stella Maris, Calambrone, Pisa, Italy.
  • Manca ML; Department of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy.
  • Castiglione V; Department of Developmental Neuroscience, IRCCS Stella Maris, Calambrone, Pisa, Italy.
  • Giannoni A; Department of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy.
  • Emdin M; Department of Mathematics, University of Pisa, Pisa, Italy.
  • Siciliano G; Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Pisa, Italy.
J Neuromuscul Dis ; 11(2): 375-387, 2024.
Article en En | MEDLINE | ID: mdl-38189759
ABSTRACT

Background:

Becker muscular dystrophy (BMD) is a dystrophinopathy due to in-frame mutations in the dystrophin gene (DMD) which determines a reduction of dystrophin at muscle level. BMD has a wide spectrum of clinical variability with different degrees of disability. Studies of natural history are needed also in view of up-coming clinical trials.

Objectives:

From an initial cohort of 32 BMD adult subjects, we present a detailed phenotypic characterization of 28 patients, then providing a description of their clinical natural history over the course of 12 months for 18 and 24 months for 13 of them.

Methods:

Each patient has been genetically characterized. Baseline, and 1-year and 2 years assessments included North Star Ambulatory Assessment (NSAA), timed function tests (time to climb and descend four stairs), 6-minute walk test (6MWT), Walton and Gardner-Medwin Scale and Medical Research Council (MRC) scale. Muscle magnetic resonance imaging (MRI) was acquired at baseline and in a subgroup of 9 patients after 24 months. Data on cardiac function (electrocardiogram, echocardiogram, and cardiac MRI) were also collected. Results and

conclusions:

Among the clinical heterogeneity, a more severe involvement is often observed in patients with 45-X del, with a disease progression over two years. The 6MWT appears sensitive to detect modification from baseline during follow up while no variation was observed by MRC testing. Muscle MRI of the lower limbs correlates with clinical parameters.Our study further highlights how the phenotypic variability of BMD adult patients makes it difficult to describe an uniform course and substantiates the need to identify predictive parameters and biomarkers to stratify patients.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Distrofia Muscular de Duchenne Tipo de estudio: Observational_studies / Prognostic_studies Idioma: En Revista: J Neuromuscul Dis Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Distrofia Muscular de Duchenne Tipo de estudio: Observational_studies / Prognostic_studies Idioma: En Revista: J Neuromuscul Dis Año: 2024 Tipo del documento: Article